Grifols and CRB invest EUR 4 million in Mecwins technology

By 22 October, 20182018, Media, News

Grifols, through Progenika Biopharma, and CRB Inverbío undersign EUR 2 million of Mecwins’ capital increase each. The total investment of EUR 4 million will allow Mecwins to complete the introduction of the technology into the Life Sciences Market and to conduct clinical trials to demonstrate the diagnostic capabilities of its ultra-sensitive technology (a million times higher than that used in routine clinical practice).

More details